Topics

A Master Protocol Empowering Precision Research in Colorectal Cancer

2019-10-15 11:11:04 | BioPortfolio

Summary

AlphaOmega is part of a new class of master protocols that represent a new subset of observational trials designed to empower a bi-directional collaboration between pre-clinical and clinical research, an essential prerequisite to feed and implement precision oncology.

AlphaOmega is a patient-centered translational research platform supporting the AIRC 5x1000 grant "Insights into the evolving heterogeneity in Metastatic colorectal cancer: from mechanisms to therapies".

Description

The study will enroll at least 500 CRC patients. Patients will be tracked from study entry through their course of treatments, until death or a minimum of 5 years. Patients will be longitudinally sampled and matched clinical data (including imaging) will be collected. Derived molecular/biological profiles will be matched with clinical characteristics to identify markers that may have prognostic and/or predictive correlation with clinical progression and individual response to treatment. Via a multi-tiered informed consensus process, AlphaOmega will also allow to develop companion diagnostics for molecular enrichment strategies in experimentally-driven proof-of-concept trials.

Study Design

Conditions

Colorectal Cancer

Intervention

Observation

Location

ASST Papa Giovanni XXIII Oncologia Medica
Bergamo
BG
Italy
24127

Status

Not yet recruiting

Source

IFOM, The FIRC Institute of Molecular Oncology

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-15T11:11:04-0400

Clinical Trials [2433 Associated Clinical Trials listed on BioPortfolio]

Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma

The optimal duration of systemic treatment in patients with advanced colorectal cancer is unknown. In this study the effects of bevacizumab and low-dose continuous chemotherapy with ...

Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

RATIONALE: The use of intrauterine levonorgestrel may prevent atypical endometrial hyperplasia and endometrial cancer in women with hereditary non-polyposis colorectal cancer or Lynch synd...

CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer

This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on progression free survival (PFS) defined as the time from start of treatment until the objective observ...

The Characterization of Small and Diminutive Colonic Polyps in LCI

Colorectal cancer is a maior cause of morbidity and mortality worldwide.Colonoscopy and removal of all adenomas is the most efficient method to prevent colorectal cancer.The most colorecta...

Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients

This study makes an observation over the objective response rate of Apatinib and 5-Fu combination regimen in the three-line treatment of metastatic colorectal cancer. All the participants ...

PubMed Articles [15392 Associated PubMed Articles listed on BioPortfolio]

Mechanisms of immunogenicity in colorectal cancer.

The immune response in cancer is increasingly understood to be important in determining clinical outcomes, including responses to cancer therapies. New insights into the mechanisms underpinning the im...

TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer.

Platelets have been shown to promote the growth of tumors, including colorectal cancer. The RNA profile of tumor-educated platelets has the possibility for cancer diagnosis. We used RNA sequencing to ...

Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma.

Clinical and experimental evidence suggests that colorectal mucosal microbiota changes during colorectal carcinogenesis and may impair colorectal anastomotic wound healing. Thus, we hypothesized that ...

The involvement of miR-150/β-catenin axis in colorectal cancer progression.

Colorectal cancer remains as a serious global cause of morbidity and mortality. The current therapies for colorectal cancer treatment are still unsatisfactory and thus, identification of novel targets...

Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer

Tumour budding is defined as the presence of a cluster of fewer than 5 cells along the invasive margin. It may confer a worse prognosis in colorectal cancer, but its importance in pT2N0 colorectal can...

Medical and Biotech [MESH] Definitions

Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with the formation of colorectal cancer (MCC stands for mutated in colorectal cancer).

Tumor suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colorectal cancer (DCC stands for deleted in colorectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.

A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.

Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.

More From BioPortfolio on "A Master Protocol Empowering Precision Research in Colorectal Cancer"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial